for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cullinan Oncology Inc

CGEM.O

Latest Trade

31.39USD

Change

-0.82(-2.55%)

Volume

102,345

Today's Range

31.06

 - 

32.48

52 Week Range

26.57

 - 

59.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
32.21
Open
32.08
Volume
102,345
3M AVG Volume
5.94
Today's High
32.48
Today's Low
31.06
52 Week High
59.85
52 Week Low
26.57
Shares Out (MIL)
43.52
Market Cap (MIL)
1,401.65
Forward P/E
--
Dividend (Yield %)
--

Next Event

Cullinan Oncology Inc Annual Shareholders Meeting

Latest Developments

More

Cullinan Oncology Reports Q1 Net Income Of $1.4 Mln

Cullinan Oncology Reports Full Year 2020 Financial Results And Business Highlights

Cullinan Management Inc Withdraws Ind Application For Cln-049 In Relapsed/Refractory Aml

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cullinan Oncology Inc

Cullinan Oncology, Inc., formerly Cullinan Management, Inc. is a biopharmaceutical company. The Company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.

Industry

Business Services

Contact Info

One Main Street, Suite 520

CAMBRIDGE, MA

02142

United States

+1.617.4104650

Executive Leadership

Patrick A. Baeuerle

Co-Founder, Chief Scientific Officer - Biologics

Jeff Trigilio

Chief Financial Officer

Leigh Zawel

Chief Scientific Officer - Small Molecules

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-5.480

2021(E)

-1.370
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up